CD274 and melanoma: Kanjanapan and Yip recently published a cohort study of 327 patients with primarily NSCLC (36%) and melanoma (47%).43 The majority (77%) of patients had PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy; 9% had CTLA-4 therapy; and 14% had combination therapy.